Business Description
Compass Therapeutics Inc
NAICS : 541714
SIC : 2834
ISIN : US20454B1044
Share Class Description:
CMPX: Ordinary SharesTotal Employee Number:
39Description
Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 19.88 | |||||
Equity-to-Asset | 0.91 | |||||
Debt-to-Equity | 0.05 | |||||
Debt-to-EBITDA | -0.13 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -6.2 | |||||
3-Year EPS without NRI Growth Rate | -4.2 | |||||
3-Year FCF Growth Rate | 1.5 | |||||
3-Year Book Growth Rate | -8.4 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 33.98 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 86.98 | |||||
9-Day RSI | 71.8 | |||||
14-Day RSI | 58.03 | |||||
3-1 Month Momentum % | -62.59 | |||||
6-1 Month Momentum % | -60.93 | |||||
12-1 Month Momentum % | -23.77 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 19.04 | |||||
Quick Ratio | 19.04 | |||||
Cash Ratio | 18.94 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -12.2 | |||||
Shareholder Yield % | -2.02 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -42.8 | |||||
ROA % | -37.7 | |||||
ROIC % | -621.96 | |||||
3-Year ROIIC % | -524.63 | |||||
ROC (Joel Greenblatt) % | -847.29 | |||||
ROCE % | -44.81 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 2.25 | |||||
Price-to-Tangible-Book | 2.25 | |||||
EV-to-EBIT | -3.15 | |||||
EV-to-Forward-EBIT | -2.61 | |||||
EV-to-EBITDA | -3.21 | |||||
EV-to-Forward-EBITDA | -2.61 | |||||
EV-to-Forward-Revenue | 209.45 | |||||
EV-to-FCF | -4.44 | |||||
| Price-to-Net-Current-Asset-Value | 2.39 | |||||
| Price-to-Net-Cash | 2.39 | |||||
Earnings Yield (Greenblatt) % | -31.75 | |||||
FCF Yield % | -12.65 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:CMPX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Compass Therapeutics Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -0.41 | ||
| Beta | 1.1016 | ||
| 3-Year Sharpe Ratio | 0.32 | ||
| 3-Year Sortino Ratio | 0.63 | ||
| Volatility % | 102.77 | ||
| 14-Day RSI | 58.03 | ||
| 14-Day ATR ($) | 0.138099 | ||
| 20-Day SMA ($) | 2.109 | ||
| 12-1 Month Momentum % | -23.77 | ||
| 52-Week Range ($) | 1.61 - 6.88 | ||
| Shares Outstanding (Mil) | 180.09 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Compass Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Compass Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-05 | In 119 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-11 08:00 | In 34 days | ||
| Second quarter earnings results for 2026 | 2026-08-11 07:00 | In 34 days | ||
| General meeting for 2026 | 2026-06-10 09:00 | 2.06 (+0.98%) | ||
| Goldman Sachs 47th Annual Global Healthcare Conference | 2026-06-09 08:00 | 2.02 (-0.98%) | ||
| Jefferies Global Healthcare Conference | 2026-06-04 08:45 | 2.10 (+0.96%) | ||
| Guidance call for 2026 | 2026-05-20 11:30 | 1.81 (+0.56%) | ||
| H.C. Wainwright 4th Annual BioConnect Investor Conference | 2026-05-19 13:30 | 1.83 (-1.61%) | ||
| First quarter earnings results for 2026 | 2026-05-05 | 1.94 (-3.00%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-05 07:30 | 5.69 (+1.79%) |
Show
Entries
Compass Therapeutics Inc Frequently Asked Questions
What is Compass Therapeutics Inc(CMPX)'s stock price today?
The current price of CMPX is $2.34. The 52 week high of CMPX is $6.88 and 52 week low is $1.61.
When is next earnings date of Compass Therapeutics Inc(CMPX)?
The next earnings date of Compass Therapeutics Inc(CMPX) is 2026-08-11 Est..
Does Compass Therapeutics Inc(CMPX) pay dividends? If so, how much?
Compass Therapeutics Inc(CMPX) does not pay dividend.
Guru Commentaries on NAS:CMPX
No articles.
Press Release
Articles on Compass Therapeutics Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers